Literature DB >> 22673924

Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.

Mustafa Akcam1, Aslihan Boyaci, Ozgur Pirgon, Selcuk Kaya, Senem Uysal, Bumin N Dundar.   

Abstract

OBJECTIVE: The aim of the study was to determine whether metformin or vitamin E treatment for six months is effective in reducing body weight, blood pressure, and also ameliorating insulin resistance, adiponectin, and tumor necrosis factor (TNF)-alpha in obese adolescents with non-alcoholic fatty liver disease (NAFLD).
METHODS: Sixty-seven obese adolescents with liver steatosis (age range, 9 - 17 years) were included in the study. The metformin group received an 850-mg dose of metformin daily and the vitamin E group received 400 U vitamin E /daily, in capsule form for 6 months, plus an individually tailored diet, exercise, and behavioral therapy.
RESULTS: After 6 months later, there was a significant decline in body mass index, and fasting insulin and homeostatic model assessment (HOMA) values in all three groups. Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study. There were no significant differences for changes of adiponectin, TNF-alpha, in all three groups after 6 months study.
CONCLUSION: These data suggest that metformin treatment is more effective than dietary advice and vitamin E treatment in reducing insulin resistance, and also in ameliorating metabolic parameters such as fasting insulin and lipid levels, in obese adolescents having NAFLD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22673924     DOI: 10.1024/0300-9831/a000086

Source DB:  PubMed          Journal:  Int J Vitam Nutr Res        ISSN: 0300-9831            Impact factor:   1.784


  7 in total

Review 1.  Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Authors:  Tannaz Eslamparast; Sareh Eghtesad; Hossein Poustchi; Azita Hekmatdoost
Journal:  World J Hepatol       Date:  2015-02-27

2.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

Review 3.  Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease.

Authors:  Peter R Baker; Jacob E Friedman
Journal:  J Clin Invest       Date:  2018-08-31       Impact factor: 14.808

4.  Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease.

Authors:  Changxi Chen; Hongliang Li; Jian Song; Cheng Zhang; Mengting Li; Yushan Mao; Aiming Liu; Juan Du
Journal:  PPAR Res       Date:  2022-02-18       Impact factor: 4.964

Review 5.  S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent.

Authors:  Rosa M Pascale; Maria M Simile; Diego F Calvisi; Claudio F Feo; Francesco Feo
Journal:  Cells       Date:  2022-01-25       Impact factor: 6.600

6.  Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Oluyemi Komolafe; Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas Jg Chase; Dominic Fritche; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-07-19

Review 7.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease.

Authors:  V Bradford; Jf Dillon; Mh Miller
Journal:  Hepat Med       Date:  2013-12-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.